» Authors » Zachariah DeFilipp

Zachariah DeFilipp

Explore the profile of Zachariah DeFilipp including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 143
Citations 2244
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Munshi P, Olin R, Wall S, McCurdy S, Al-Juhaishi T, Baker J, et al.
Transplant Cell Ther . 2025 Feb; PMID: 39961473
Geriatric assessment (GA) may identify vulnerabilities and promote risk-stratification in older adults predisposed to toxicities after autologous (auto), allogeneic (allo) hematopoietic cell transplantation (HCT) and chimeric antigen T-cell therapies (CAR...
2.
El-Jawahri A, Reese J, Traeger L, Dizon D, Cutler C, Bober S, et al.
J Natl Compr Canc Netw . 2025 Feb; 23(2). PMID: 39938468
Background: Interventions to address sexual health in hematopoietic stem cell transplant (HSCT) survivors are limited. Methods: We conducted a pilot randomized trial of a digital app, SHIFT (Sexual Health and...
3.
Frigault M, Yao E, Berger T, Wehrli M, Gallagher K, Horick N, et al.
Blood Adv . 2025 Feb; PMID: 39928957
Chimeric antigen receptor T (CAR-T) cell therapy is limited by cytokine release syndrome (CRS) and neurotoxicity (NT). We sought to use once-daily prophylactic anakinra, an IL-1R antagonist, to prevent CRS/NT...
4.
Katsivelos N, Spyrou N, Weber D, Vasova I, Ayuk F, Choe H, et al.
Transplant Cell Ther . 2024 Dec; 31(1):10.e1-10.e9. PMID: 39667999
Background: The standard treatment for acute graft-vs-host disease (GVHD), a common complication following allogeneic hematopoietic cell transplant, remains prolonged courses of high dose corticosteroids. Previous attempts to decrease corticosteroid exposure...
5.
DeFilipp Z
Blood . 2024 Nov; 144(22):2273-2274. PMID: 39607712
No abstract available.
6.
Somasundaram E, Gill R, Hartford N, Collier K, McAfee S, Dey B, et al.
Transplant Cell Ther . 2024 Nov; 31(1):45.e1-45.e7. PMID: 39542361
Hematopoietic cell transplantation (HCT) remains the definitive therapeutic modality for numerous malignant and non-malignant hematologic disorders. Conventional bone marrow remains a viable donor source for HCT. However, microbial contamination of...
7.
DeFilipp Z, Fox L, Holderried T, Mehra V, Michonneau D, Pashley A, et al.
Transplant Cell Ther . 2024 Nov; 31(2):76.e1-76.e13. PMID: 39536878
The objective of this meta-analysis (MA) was to evaluate the efficacy and safety of extracorporeal photopheresis (ECP) for the treatment of steroid-refractory chronic graft-versus-host disease (SR-cGvHD). A systematic literature review...
8.
Pidala J, Pidala J, Kim J, Kalos D, Cutler C, Cutler C, et al.
Blood Adv . 2024 Oct; 9(5):1040-1048. PMID: 39454280
To examine the activity of ibrutinib in steroid-refractory chronic graft-versus-host disease (SR-cGVHD) after the US Food and Drug Administration approval, we conducted a multicenter retrospective study. Data were standardly collected...
9.
DeFilipp Z, Kim H, Cheng G, Hamilton B, Chhabra S, Hamadani M, et al.
Blood Adv . 2024 Oct; 9(2):244-253. PMID: 39365992
Bronchiolitis obliterans syndrome (BOS) occurring after allogeneic hematopoietic cell transplantation (HCT) is a high-risk manifestation of chronic graft-versus-host disease. In this prospective, multicenter phase 2 trial, adult participants with BOS...
10.
Iftikhar R, DeFilipp Z, DeZern A, Pulsipher M, Bejanyan N, Burroughs L, et al.
Transplant Cell Ther . 2024 Sep; 30(12):1155-1170. PMID: 39307421
Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for severe aplastic anemia (SAA). Existing guidance about HCT in SAA is primarily derived from expert reviews, registry data and...